2023 / 04

Next Paper
DOI: 10.24075/medet.2023.032

ORIGINAL RESEARCH

Ethical issues of pharmacogenetics of anti-relapse therapy in patients with alcohol dependence syndrome

Lileeva EG1, Speshilova SA1, Zinoveva MA1,2
About authors

1 Yaroslavl State Medical University, Yaroslavl, Russia

2 Yaroslavl Regional Clinical Narcological Hospital, Yaroslavl, Russia

Correspondence should be addressed: Elena G. Lileeva
Revolutsionnaya Str., 5, Yaroslavl, 150000, Russia; ur.xednay@6002aveelile

About paper

Author contribution: the authors reviewed literature data on pharmacogenetic research in patients with alcohol dependence syndrome. The authors made an equal contribution to the article.

Received: 2023-10-13 Accepted: 2023-11-26 Published online: 2023-12-21
|
  1. Kozhinova TA. Formation and course of alcoholism in men with various character accentuations according to inpatient examination data. Dissertation for the degree of Doctor of Medical Sciences. M., 2019; 4 s. Russian.
  2. Kirzhanova VV, Grigorova NI, Bobkov EN, Kirzhanov VN, Sidoryuk OV. Activities of drug treatment services in the Russian Federation in 2020–2021: Analytical review. 2022; 24 s. Russian.
  3. Hart AB, Kranzler HR. Alcohol dependence genetics: lessons learned from genome-wide association studies (GWAS) and post-GWAS analyses. Alcohol Clin Exp Res. 2015; 39 (8)1312–1327. DOI: 10.1111/acer.12792
  4. Kibitov AO. Genetic aspects of narcological diseases. Monograph. M., 2021; 312 s. Russian.
  5. Hall FS, Drgonova J, Jain S, Uhl GR. Implications of genome wide association studies for addiction: are our a priori assumptions all wrong? Pharmacol Ther. 2013; 140(3): 267–279. DOI: 10.1016/j.pharmthera.2013.07.006.
  6. Krupitsky EM, Kibitov AO, Blokhina EA, Verbitskaya EV, Brodyansky VM, Alekseeva NP, Bushara NM, Yaroslavtseva TS, Palatkin VYa, Masalov DV, Burakov AM, Romanova TN, Sulimov GYu, Kosten T, Nielsen D, Zvartau EE, Woody D. Stabilization of remissions in patients with opium addiction Naltrexone implant: pharmacogenetic aspect. Zhurnal nevrologii i psikhiatrii im. S. S. Korsakova. 2015; 115 (4): 14–23. Russian.
  7. Suzuki Y, Yokoyama A, Nakano M, Okuyama K, Takahashi H, Tamai H, Maruyama K and Ishii H. Cyanamide-induced liver dysfunction after abstinence in alcoholics: a long-term follow-up study on four cases. Alcoholism: Clinical and Experimental Research. 2000; 24: 100–105.
  8. Al-Eitan LN, Jaradat SA, Su SY, Tay GK, Hulse GK. Mu opioid receptor (OPRM1) as a predictor of treatment outcome in opiate-dependent individuals of Arab descent. Pharmgenomics Pers Med. 2012; 5: 99–111. DOI: 10.2147/PGPM.S33351.
  9. Mutschler J, Abbruzzese E, Witt SH, Dirican G, Nieratschker V, Frank J, Kiefer F. Functional poly-morphism of the dopamine β-hydroxylase gene is associated with increased risk of disulfiram-induced adverse effects in alcohol-dependent patients. Journal of clinical psychopharmacology. 2012; 32 (4): 578–580. DOI: 10.1097/JCP.0b013e31825ddbe6.
  10. Ivanets NN, Vinnikova MA, Kozyreva AV. Results of clinical and catamnestic comparative study of the drug Cyanamide in the treatment of alcohol dependence. Issues of narcology. 2006; 2: 21–29. Russian.
  11. Krupitsky EM, Akhmetova EA, Asadullin AR. Pharmacogenetics of chemical addictions. Review of psychiatry and medical psychology. 2019; (4–1): 12–20. Russian.
  12. Arias AJ, Armeli S, Gelernter J, Covault J, Kallio A, Karhuvaara S, Kranzler HR. Effects of opioid receptor gene variation on targeted nalmefene treatment in heavy drinkers. Alcoholism: Clinical and Experimental Research. 2008; 32(7): 1159–1166. DOI: 10.1111/j.1530-0277.2008.00735.
  13. Krupitsky EM, Rybakova KV, Skurat EP, Mikhailov AD, Neznanov NG. Double-blind, randomized, placebo-controlled study of the effectiveness of the use of pregabalin for the treatment of alcohol dependence syndrome. Voprosy narkologii. 2017; 8: 81–82. Russian.
  14. Edenberg HJ, Kranzler HR. The contribution of genetics to addiction therapy approaches. Pharmacol Ther. 2005; 108(1): 86–93.